Impetigo Treatment
For limited impetigo, treat with topical mupirocin 2% or retapamulin 1% ointment twice daily for 5 days; for extensive disease, multiple lesions, or outbreaks, use oral antibiotics—specifically dicloxacillin or cephalexin for 7 days targeting methicillin-susceptible S. aureus (MSSA), or clindamycin, doxycycline, or trimethoprim-sulfamethoxazole when MRSA is suspected. 1
Treatment Algorithm
Step 1: Assess Disease Extent
- Limited disease (few localized lesions): Topical therapy is appropriate
- Extensive disease (numerous lesions, multiple body sites): Oral therapy required
- Outbreak settings: Oral therapy mandatory to reduce transmission 1
Step 2: Choose Topical vs. Systemic Therapy
Topical Antibiotics (First-line for limited disease):
- Mupirocin 2% ointment applied twice daily for 5 days 1, 2
- Retapamulin 1% ointment applied twice daily for 5 days 1, 2
- Both have strong evidence and high-quality recommendations for nonbullous and bullous impetigo
Oral Antibiotics (Required for extensive disease):
For MSSA (most common):
- Dicloxacillin 250 mg four times daily (adults) 1
- Cephalexin 250-500 mg four times daily (adults); 25-50 mg/kg/day in 3-4 divided doses (children) 1
- Duration: 7 days 1
For MRSA (suspected or confirmed):
- Clindamycin 300-400 mg four times daily (adults); 20-30 mg/kg/day in 3 divided doses (children) 1
- Doxycycline 100 mg twice daily (not for children <8 years) 1
- Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily (adults); 8-12 mg/kg/day based on trimethoprim component (children) 1
Step 3: Special Considerations
When cultures yield streptococci alone: Oral penicillin becomes the agent of choice 1
During outbreaks of poststreptococcal glomerulonephritis: Systemic antimicrobials are mandatory to eliminate nephritogenic strains from the community 1
Ecthyma (deeper variant): Always requires oral antibiotic therapy, not topical 1
Critical Clinical Pitfalls
⚠️ Avoid penicillin monotherapy for empiric treatment—it lacks adequate S. aureus coverage, which causes the majority of impetigo cases 3
⚠️ Erythromycin resistance is common in both S. aureus and S. pyogenes; use with caution and only when susceptibility is confirmed 1
⚠️ Trimethoprim-sulfamethoxazole covers MRSA effectively but has inadequate streptococcal coverage—reserve for confirmed MRSA or use with caution in mixed infections 3
⚠️ Topical disinfectants are inferior to antibiotics and should not be used as primary therapy 3
Evidence Quality Discussion
The IDSA 2014 guidelines 1 provide the strongest framework, with "strong, high" quality evidence for topical mupirocin and retapamulin, and "strong, moderate" evidence for oral therapy selection. These recommendations are reinforced by recent systematic reviews 2, 4 showing topical antibiotics have comparable efficacy to systemic agents for limited disease, supporting antibiotic stewardship principles.
The guideline's recommendation for 5-day topical therapy and 7-day oral therapy is based on clinical trial data demonstrating adequate cure rates at these durations 1. Shorter courses risk treatment failure; longer courses provide no additional benefit.
Resistance Considerations
Rising MRSA prevalence has shifted empiric therapy considerations 3. When MRSA is epidemiologically likely (previous MRSA infection, endemic areas, treatment failure), initial therapy should target resistant organisms. However, most impetigo remains MSSA-predominant, making narrow-spectrum agents like dicloxacillin and cephalexin appropriate first-line choices 1.